1. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity—I. Disease modifying action on adjuvant arthritis of the rat;Bartlett;Int J Immunopharmacol,1985
2. Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappa B;Imose;Hepatology,2004
3. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis;Manna;J Immunol,2000
4. Leflunomide: mode of action in the treatment of rheumatoid arthritis;Breedveld;Ann Rheum Dis,2000
5. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression;Manna;J Immunol,1999